EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

Sarah Alrubia iD, Brahim Achour, Zubida M Al-Majdoub, Amin Rostami-Hodjegan, Jill Barber

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Sarah Alrubia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Crohn Disease, Intestinal Absorption, Membrane Transport Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Saudi Ministry of Education, King Saud University, KSA, Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.

Methods

Homogenate fractions were processed from 13 inflamed (six ileum and seven colon) and seven non‐inflamed (two ileum and five colon) CD and 10 healthy (five ileum and five colon) tissues from deceased subjects by calcium chelation elution, and protein abundances determined by liquid chromatography–tandem mass spectrometry (LC–MS/MS)‐based proteomics and compared with healthy values. PBPK simulation was applied to predict the potential effect of altered DMET profiles on the PK of oral drugs.

Results

All investigated proteins showed trends for reduced expression in inflamed and non‐inflamed CD samples relative to healthy individuals. Significant downregulation ( P < 0.05) was observed for CYP3A4, AOX1, NAT1 and several SULTs in inflamed ileum as well as UGT1A10, NAT1, BCRP and several SULTs in inflamed and non‐inflamed colon. Inter‐individual variability was generally higher in CD, with exceptions, for most targets (up to 146%CV in inflamed ileum and up to 169% in histologically normal colon tissues). Integration of abundance data into a verified PBPK model of CD showed a considerable (≥2‐fold; CD predicted relative to healthy predicted) change in systemic drug exposure for 10 drugs examined.

Conclusions

CD inflammation significantly suppresses the expression of intestinal DMETs, which, together with changes in other system parameters, can alter the fate of drugs taken orally in these patients. Virtual patients within a PBPK framework, informed by the measured DMET ranges in the intestine, may serve as a guide for dose adjustment in the absence of dedicated clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseIntestinal AbsorptionMembrane Transport ProteinsHumansAdministration, OralIleumMaleAdultFemaleModels, BiologicalColonMiddle AgedProteomicsCase-Control StudiesTandem Mass SpectrometryIntestinal Mucosa

Stichwörter der Autor:innen

Crohn's diseasePBPKdrug‐metabolizing enzymesintestineoral drugspharmacokineticsproteomics

Substanzen

Membrane Transport Proteins

Autor:innen und Institutionen

  • Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester, UK.
  • Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island, USA.
  • Certara Predictive Technologies, Certara Inc., Sheffield, UK.

ORCID-Profile: Sarah Alrubia

Förderung

  • Saudi Ministry of Education, King Saud University, KSA
  • Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, UK

Zitieren

APA

Alrubia, S., Achour, B., Al-Majdoub, Z. M., Rostami-Hodjegan, A., & Barber, J. (2025). Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70019

Vancouver

Alrubia S, Achour B, Al-Majdoub ZM, Rostami-Hodjegan A, Barber J. Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70019

BibTeX
@article{Alrubia2025,
  author = {Alrubia, Sarah and Achour, Brahim and Al-Majdoub, Zubida M and Rostami-Hodjegan, Amin and Barber, Jill},
  title = {Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70019}
}
Kostenlos starten →